Abstract
Medulloblastoma (MB) is one of the most common malignant tumors with poor survival in children. Nuclear factor erythroid 2-related factor2 (Nrf-2) and heme oxygenase-1 (HO-1) have been considered to play major roles in the pathogenesis of many tumors. There is no report about clinicopathological significance of Nrf-2 and HO-1 expression in medulloblastoma. In the present study, to explore the expression and potential function of Nrf-2 and HO-1 in MBs, immunohistochemistry was used to examine the Nrf-2 and HO-1 expression in 41 MBs and 27 control tissues adjacent to the tumor. The results showed that in the cases of MB, the positive expression rates of Nrf-2 and HO-1 (82.9% and 78.0%) were significantly increased compared with that (37.0% and 29.6%) in peritumoral control brain tissues. The difference was statistically significant (P 0.05). The abnormal expression of Nrf-2 and HO-1 in MB suggest that the Nrf-2/HO-1 pathway plays an important role in the formation and development of MB and may be a potential therapeutic target for MB.
Highlights
Medulloblastomas (MB) is one of the most common malignant central nervous system (CNS) tumors in children [1] [2]
nuclear factor erythroid2-related factor 2 (Nrf-2) and heme oxygenase-1 (HO-1) expression levels were studied in 41 MB and 27 control brain tissue adjacent to the tumor by immunohistochemistry
We employed immunohistochemistry to evaluate the expression of Nrf-2 and HO-1 in MB and normal brain tissues
Summary
Medulloblastomas (MB) is one of the most common malignant central nervous system (CNS) tumors in children [1] [2]. The cells have high mitotic activity and ability to spread throughout the CNS, and the poor survival rates is partly due to the lack of effective treatment. The current studies found that the antioxidant and anti-inflammatory effects of many drugs occurred through activation of the nuclear factor erythroid2-related factor 2 (Nrf-2)/heme oxygenase-1 (HO-1) pathway. Nrf-2 and HO-1 expression levels were studied in 41 MB and 27 control brain tissue adjacent to the tumor by immunohistochemistry. The correlations and clinicopathological factors were investigated to clarify the potential target for MB treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have